Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you offer ultrahypofractionated 5 fraction breast radiation to a patient with lupus?
Answer from: Radiation Oncologist at Community Practice
Favor partial breast over whole breast if feasible.APBI or IMPORT LOW volume and FAST-Forward dose of 26 in 5.
Sign in or Register to read more
17734
Related Questions
How would you approach the treatment of low grade, stage IA, triple negative apocrine adenocarcinoma of the breast in a female patient in her 70s?
Is stage I B/L breast, ER+ cancer a contraindication to breast radiation omission after breast conservation surgery?
What are your top takeaways in Breast Cancer from ASCO 2025?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?
What is your approach to women with breast cancer who opts for a staged approach with up-front lumpectomy and SLN biopsy (pN-) when there are indications for adjuvant radiation therapy but she plans for a later mastectomy (=>6 months)?
How do you approach boost to the lumpectomy cavity AND 4 lymph nodes with extra-nodal extension when treating breast cancer with hypofractionation?
If a patient has multiple PET-avid level 3, supraclavicular, or IMN nodes that are small and would have been considered negative by size criteria with traditional imaging, that are no longer positive on PET after chemotherapy, would you try to boost these nodes?
Does a post-surgical hematoma in the breast affect your recommendations for partial breast RT?
How do you weigh upfront nodal burden when deciding to omit PMRT in a patient with cN1, ypN0 disease after neoadjuvant chemo, mastectomy and ALND?
Should PMRT be offered for ypN0(i+) disease if only 1-2 nodes were removed in the post-chemotherapy SLNB and there is no plan for a completion AxLND?